<DOC>
	<DOCNO>NCT01007851</DOCNO>
	<brief_summary>GnRH agonist administration luteal phase report beneficially affect clinical outcome ICSI-ET cycle . This randomize controlled trial evaluates effect single dose GnRH agonist administer luteal phase outcome ICSI - ET cycle stimulate fixed GnRH antagonist protocol . Women undergo embryo transfer follow control ovarian hyperstimulation fix GnRH antagonist protocol include . In addition routine luteal phase support progesterone woman randomize receive single dose GnRH agonist placebo sixth day ICSI.Ongoing pregnancy rate primary outcome measure .</brief_summary>
	<brief_title>Single Dose Gonadotropin-releasing Hormone ( GnRH ) Agonist Administration Luteal Phase GnRH Antagonist Stimulated ICSI-ET Cycles</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Women undergo embryo transfer follow control ovarian hyperstimulation fix GnRH antagonist protocol , oocyte pickup ICSI . Embryo transfer perform day 3 Participation another trial conduct unit time . Preimplantation genetic screening cycle . Day 5 embryo transfer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>GnRH agonist</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>IVF</keyword>
	<keyword>ICSI</keyword>
	<keyword>assist reproduction</keyword>
	<keyword>luteal phase</keyword>
</DOC>